Nasdaq |
Lilly/Incyte pill beats placebo in mid-stage eczema trial
Reuters The Phase 2 eczema trial found that after 16 weeks, 61 percent of patients on the highest dose of baricitinib and a topical corticosteroid had at least a 50 percent reduction in symptoms, compared to 37 percent of patients treated with just a steroid … Olumiant improves outcomes in patients with atopic dermatitis Lilly Announces New Safety And Efficacy Data From Phase 2 Study Of Baricitinib |